Relmada Therapeutics, Inc. RLMD Preferred Stock, Par or Stated Value Per Share
Preferred Stock, Par or Stated Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s preferred stock, par or stated value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s preferred stock, par or stated value per share?
- Relmada Therapeutics, Inc. (RLMD) reported preferred stock, par or stated value per share of $0 in Q1 2026.
- How has Relmada Therapeutics, Inc.'s preferred stock, par or stated value per share changed year-over-year?
- Relmada Therapeutics, Inc.'s preferred stock, par or stated value per share decreased by 0.0% year-over-year, from $0 to $0.
- What is the long-term trend for Relmada Therapeutics, Inc.'s preferred stock, par or stated value per share?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s preferred stock, par or stated value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.